Ketamine Advances as Treatment for Levodopa-induced Dyskinesia

Ketamine Advances as Treatment for Levodopa-induced Dyskinesia

294657

Ketamine Advances as Treatment for Levodopa-induced Dyskinesia

The U.S. Food and Drug Administration (FDA) has approved PharmaTher‘s investigational new drug (IND) application for ketamine as a treatment for levodopa-induced dyskinesia in people with Parkinson’s disease. The approval clears the way for PharmaTher to proceed with a Phase 2 clinical trial to study low-dose ketamine — an anesthetic available by prescription in the U.S. — in Parkinson’s disease. “The FDA’s acceptance of our IND application for ketamine to treat Parkinson’s disease is a significant milestone…

You must be logged in to read/download the full post.